This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities. There will be no public offer of the securities in any jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. An investment decision regarding the securities referred to herein should only be made on the basis of the securities prospectus.
This announcement is an advertisement and does not, under any circumstances, constitute a public offering or an invitation to the public in connection with any offer within the meaning of Regulation (EU) 2017/1129. The final prospectus, when published, will be available on the website of the Luxembourg Stock Exchange (www.luxse.com).
The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons.
The tender offer referenced herein is not being made, directly or indirectly, in or into the United States by use of the mails or by any means or instrumentality (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of any facility of a national securities exchange of the United States and the tender offer cannot be accepted by any such use, means, instrumentality or facility or from within the United States.
Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
Basis of accessAccess to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer.
Confirmation of understanding and acceptance of disclaimerBy clicking on the "I AGREE" button, I certify that I am not located in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is prohibited or restricted.
I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the "I AGREE" button, I confirm that I am permitted to proceed to electronic versions of these materials.
- Australia
- Japan
- Canada
- South Africa
- USA
- Other
The following materials are not directed at or to be accessed by persons located in the United States, Australia, Canada or Japan. These materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States, Australia, Canada or Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any person to whom it is unlawful to make such offer or solicitation.
The securities mentioned herein have not been, and will not be, registered under the Securities Act and may not be offered or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will be no public offer of the securities in the United States.
In the United Kingdom the following materials are only directed at (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (ii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on the materials or any of their contents.
In relation to each member state of the European Economic Area which has implemented the Directive 2003/71/EC, and any amendments thereto (the "Prospectus Directive")(each a "Relevant Member State"), an offer to the public of the securities has not been made and will not be made in such Relevant Member State, except that an offer to the public in such Relevant Member State of any securities may be made at any time under the following exemptions from the Prospectus Directive, if they have been implemented in the Relevant Member State:
- to any legal entity which is a qualified investor as defined in the Prospectus Directive,
- to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, or
- in any other circumstances falling within Article 3(2) of the Prospectus Directive;
provided that no such offer shall result in a requirement to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive.
For the purposes of this provision, the expression an "offer to the public" in relation to any securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any securities, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State, and the expression "Prospectus Directive" includes any relevant implementing measure in each Relevant Member State.
Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
Basis of accessAccess to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer.
Confirmation of understanding and acceptance of disclaimerBy clicking on the "I AGREE" button, I certify that I am not located in the United States, Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or restricted.
I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the "I AGREE" button, I confirm that I am permitted to proceed to electronic versions of these materials.
- Australia
- Japan
- Canada
- South Africa
- USA
- Other
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities. There will be no public offer of the securities in any jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. An investment decision regarding the securities referred to herein should only be made on the basis of the securities prospectus.
This announcement is an advertisement and does not, under any circumstances, constitute a public offering or an invitation to the public in connection with any offer within the meaning of Regulation (EU) 2017/1129. The final prospectus, when published, will be available on the website of the Luxembourg Stock Exchange (www.luxse.com).
The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons.
The tender offer referenced herein is not being made, directly or indirectly, in or into the United States by use of the mails or by any means or instrumentality (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of any facility of a national securities exchange of the United States and the tender offer cannot be accepted by any such use, means, instrumentality or facility or from within the United States.
Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
Basis of accessAccess to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer.
Confirmation of understanding and acceptance of disclaimerBy clicking on the "I AGREE" button, I certify that I am not located in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is prohibited or restricted.
I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the "I AGREE" button, I confirm that I am permitted to proceed to electronic versions of these materials.
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities. There will be no public offer of the securities in any jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. An investment decision regarding the securities referred to herein should only be made on the basis of the securities prospectus.
This announcement is an advertisement and does not, under any circumstances, constitute a public offering or an invitation to the public in connection with any offer within the meaning of Regulation (EU) 2017/1129. The final prospectus, when published, will be available on the website of the Luxembourg Stock Exchange (www.luxse.com).
The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons.
The tender offer referenced herein is not being made, directly or indirectly, in or into the United States by use of the mails or by any means or instrumentality (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of any facility of a national securities exchange of the United States and the tender offer cannot be accepted by any such use, means, instrumentality or facility or from within the United States.
Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
Basis of accessAccess to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer.
Confirmation of understanding and acceptance of disclaimerBy clicking on the "I AGREE" button, I certify that I am not located in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is prohibited or restricted.
I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the "I AGREE" button, I confirm that I am permitted to proceed to electronic versions of these materials.
- Australia
- Japan
- Canada
- South Africa
- USA
- Other
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities. There will be no public offer of the securities in any jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction.
The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold in the United States or to, or for the benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act.
Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
Basis of accessAccess to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer.
Confirmation of understanding and acceptance of disclaimerBy clicking on the "I AGREE" button, I certify that I am not located in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is prohibited or restricted.
I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the "I AGREE" button, I confirm that I am permitted to proceed to electronic versions of these materials.
- Australia
- Japan
- Canada
- South Africa
- USA
- Other
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities. There will be no public offer of the securities in any jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. An investment decision regarding the securities referred to herein should only be made on the basis of the securities prospectus.
This announcement is an advertisement and does not, under any circumstances, constitute a public offering or an invitation to the public in connection with any offer within the meaning of Regulation (EU) 2017/1129. The final prospectus, when published, will be available on the website of the Luxembourg Stock Exchange (www.luxse.com).
The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons.
Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
Basis of accessAccess to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer.
Confirmation of understanding and acceptance of disclaimerBy clicking on the "I AGREE" button, I certify that I am not located in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is prohibited or restricted.
I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the "I AGREE" button, I confirm that I am permitted to proceed to electronic versions of these materials.
This website is intended to provide information to an international audience outside the USA and UK. Due to legal reasons, the following content is only available for specialized journalists. To access these pages, please confirm that you are a medical journalist and that you would like to accredit to the Bayer press portal.
This website is intended to provide information to an international audience outside the UK. Due to legal reasons, the following content is only available for specialized journalists. To access these pages, please confirm that you are a medical journalist and that you would like to accredit to the Bayer press portal.
Group sales increase to 10.053 billion euros (reported: plus 4.1 percent; Fx & portfolio adj.: plus 1.9 percent) / EBITDA before special items rises to 1.615 billion euros (plus 6.9 percent) / Pharmaceuticals enters new growth cycle with strong top and bottomline growth / Crop Science reports lower sales (Fx & portfolio adj.) and earnings in seasonally small quarter / Consumer Health sales at prior-year level (Fx & portfolio adj.), earnings down / Core earnings per share decline to 0.31 euros, impacted by non-cash charges from interest rate changes / Net income at minus 672 million euros, including impairment losses at Pharmaceuticals and Consumer Health / Free cash flow decreases to minus 293 million euros, partly due to settlement payments / Net financial debt reduced to 31.083 billion euros / Upgraded outlook for Pharmaceuticals margin, Group EBITDA before special items and free cash flow - lower net financial debt expected
Leverkusen, November 3, 2026 - Bayer is operationally on track to deliver its full-year commitments at the nine-month mark, while also aiming to capitalize on improved trends as the year draws to a close. "We've reached a turning point in Pharma's growth trajectory and we're beginning to see the other side," CEO Bill Anderson said on Tuesday when presenting the company's Quarterly Statement for the third quarter. Led by Nubeqa™ and Kerendia™, the division demonstrates its growth potential, he explained. For the full year, Bayer now expects sales growth towards the upper end of the division's guidance range. Meanwhile, Crop Science and Consumer Health are performing in line with their targets while navigating market pressures. Against this backdrop, Bayer raised its guidance for the Pharmaceuticals margin as well as Group EBITDA before special items, free cash flow and net financial debt.
Bayer has also made major strides on key strategic topics. Last week, for instance, asundexian was granted approval in China for secondary stroke prevention under the brand name Sunharbo™. Describing it as "the biggest news out of our pipeline," Anderson explained that "asundexian is now the first approved Factor XIa inhibitor worldwide - and we're focused on obtaining additional approvals." Commending the team behind it, he said: "Our scientists in Wuppertal invented this molecule and have worked on it for more than a decade. They've embraced our operating model and AI, which allowed them to substantially compress the timeline, getting this medicine to patients a year early. Incredible impact!"
On the litigation side, the company last week secured a decision in its favor in the first glyphosate case to go to trial since the 7-2 ruling of the U.S. Supreme Court. Anderson sees this as a strong sign that Bayer's containment work is advancing. "The fact that all 12 jurors sided with the company should be informative for those seeking to pursue claims in the court system. We will continue to handle cases in the best interests of the company, and we're awaiting an important decision on the class settlement."
Sales and EBITDA before special items advance against prior year
Group sales came in at 10.053 billion euros in the third quarter of 2026, up 4.1 percent on a reported basis and 1.9 percent after adjusting for currency and portfolio effects (Fx & portfolio adj.). There was a positive currency effect of 246 million euros. EBITDA before special items increased by 6.9 percent to 1.615 billion euros, and included a positive currency effect of 36 million euros. EBIT amounted to minus 110 million euros (Q3 2025: minus 543 million euros), weighed down by an impairment loss of 307 million euros on the Xofigo™ brand within the Pharmaceuticals Division. EBIT also included net special charges of 407 million euros (Q3 2025: 1.064 billion euros) that primarily related to an impairment loss of 215 million euros on the Claritin™ brand within the Consumer Health Division, as well as litigation-related expenses. Net income came in at minus 672 million euros (Q3 2025: minus 963 million euros). Core earnings per share decreased to 0.31 euros (Q3 2025: 0.49 euros), with the improvement in operational earnings performance only partially offsetting non-cash charges from interest rate changes.
Free cash flow declined to minus 293 million euros (Q3 2025: plus 596 million euros), partly due to expected higher payments to resolve legal proceedings. Net financial debt came in at 31.083 billion euros as of September 30, 2026, representing a decline of 2.564 billion euros against June 30, 2026, and a decrease of 1.625 billion euros from a year-on-year perspective. This development was largely attributable to a payment of 3.0 billion euros from Apollo Global Management Inc. in exchange for a minority stake in a newly established entity, which was previously communicated.
Crop Science: Seed business gains partly offset crop protection headwinds
Sales in the agricultural business (Crop Science) came in at 3.884 billion euros, in line with the prior-year quarter on a reported basis (plus 0.7 percent). Adjusted for currency and portfolio effects, sales were 2.4 percent lower year on year, largely due to regulatory impacts and adverse weather conditions in Europe/Middle East/Africa and Asia/Pacific. However, these headwinds were partially offset by strong growth in Latin America, which was primarily fueled by increased demand for corn and soybean seeds for the summer season. Corn Seed & Traits sales came in at the prior-year level overall (Fx & portfolio adj. minus 0.1 percent), while business at Soybean Seed & Traits was up 4.5 percent (Fx & portfolio adj.). By contrast, the division registered declines of 8.6 percent (Fx & portfolio adj.) at both its Fungicides and Herbicides excl. Glyphosate units.
EBITDA before special items decreased by 41.3 percent to 101 million euros in the three months ending September 30, the period which typically represents the quarter with the smallest contribution to full-year earnings of the agricultural business due to seasonal factors. The decline in earnings was mainly attributable to an increase in the cost of goods sold and higher selling expenses. These negative cost-related developments partially reflected the impact of favorable effects in the prior-year period. By contrast, there was a positive currency effect of 9 million euros. The EBITDA margin before special items decreased by 1.9 percentage points to 2.6 percent.
Pharmaceuticals starts new growth cycle
Sales of prescription medicines (Pharmaceuticals) rose by 8.0 percent to 4.680 billion euros on a reported basis. Adjusted for currency and portfolio effects, sales were up 6.4 percent. Growth continued to be driven by the cancer drug Nubeqa™ and Kerendia™, for the treatment of chronic kidney disease and heart failure, with sales up 58.3 and 64.9 percent (Fx & portfolio adj.), respectively. Buoyed by these gains, Nubeqa™ sales hit approximately one billion euros in the third quarter alone, while Kerendia™ also achieved blockbuster status by surpassing the one-billion-mark in the 12 months from October 1, 2025. The Radiology business also delivered strong performance. In addition, sales of Beyonttra™, the division's product for the treatment of cardiomyopathy, were five times higher than the prior-year level, driven by significant volume gains following the product's successful market launch in Europe. By contrast, Xarelto™ and Eylea™ sales decreased as anticipated due to patent expirations. However, the rates of decline are gradually slowing, with sales of the oral anticoagulant falling 30.7 percent (Fx & portfolio adj.) and business with the ophthalmology drug down 23.5 percent (Fx & portfolio adj.). The Eylea™ 8 mg formulation offering extended treatment intervals accounted for around 60 percent of overall Eylea™ sales.
EBITDA before special items at Pharmaceuticals advanced by 23.6 percent to 1.292 billion euros. The rise in earnings was primarily driven by topline growth, which, in turn, was mainly fueled by Nubeqa™ and Kerendia™. By contrast, the division recorded an increase in selling expenses as it continues to invest in future growth. In addition, there was a positive currency effect of 30 million euros. The EBITDA margin before special items increased by 3.5 percentage points to 27.6 percent.
Consumer Health: Resilient sales (Fx & portfolio adj.) in a mixed market environment
Sales of self-care products (Consumer Health) increased by 2.1 percent to 1.445 billion euros on a reported basis. Adjusted for currency and portfolio effects, sales were level with the prior-year period (plus 0.1 percent). Business was mainly up in the Digestive Health and Dermatology categories, which saw gains of 4.5 and 3.0 percent (Fx & portfolio adj.), respectively. The topline growth in the Digestive Health business was primarily fueled by significantly higher MiraLAX™ sales in the United States, while the Dermatology category mainly benefited from gains for Bepanthen™. By contrast, business in the Nutritionals category was down 3.4 percent (Fx & portfolio adj.). Sales of cough and cold products also decreased, resulting in a decline of 2.9 percent (Fx & portfolio adj.) for the Allergy & Cold category. From a regional perspective, the division registered higher sales in Asia/Pacific and Latin America, but experienced a decline in business in Europe/Middle East/Africa against a strong prior-year quarter, as well as continued headwinds from a weak market environment in the United States.
EBITDA before special items at Consumer Health decreased by 4.4 percent to 347 million euros, with the division's continuous cost and price management efforts only partially offsetting the impact of higher investments in marketing its innovative products. In addition, earnings benefited from income from the sale of a minor, non-strategic brand. Furthermore, there was a positive currency effect of 7 million euros. The EBITDA margin before special items declined by 1.7 percentage points to 24.0 percent.
Group outlook for 2026 improved
"Our year-to-date performance is a proof point that our strategy is working, and it gives us the confidence to improve our targets for the year on adjusted EBITDA, cash and debt," said Dr. Judith Hartmann, Chief Financial Officer of Bayer. In view of the Pharmaceuticals business performance, Bayer has raised its full-year guidance for the division's EBITDA margin before special items to between 25 and 27 percent (previous forecast: between 23 and 25 percent). As a result, it now expects Group EBITDA before special items to come in at between 9.8 and 10.3 billion euros on a currency-adjusted basis (previous forecast: 9.6 to 10.1 billion euros). The company has also upgraded its free cash flow guidance, lifting the projected range by 1.0 billion euros to between minus 1.5 and minus 0.5 billion euros (previous forecast: between minus 2.5 and minus 1.5 billion euros). In this connection, Bayer now expects year-end net financial debt to come in lower than previously anticipated, with an updated range of between 28.0 and 29.0 billion euros (previous forecast: between 29.0 and 30.0 billion euros). For all other KPIs, Bayer has confirmed its Group guidance for full-year 2026 as published in the Half-Year Financial Report 2026. "We remain focused on our priorities: strengthening the balance sheet, improving productivity and cash generation, and building the financial flexibility to invest in our next generation of growth," said Hartmann.
Notes:
The following tables contain the key data for the Bayer Group and its divisions for the third quarter and the first nine months of 2026.
The full Quarterly Statement for the third quarter is available online at:
www.bayer.com/quarterly-statement
The speech given by Bill Anderson and Dr. Judith Hartmann to the media will be available online from around 10 a.m. CET at:www.bayer.com/speeches
Live broadcast of the Media Update from around 10 a.m. CET and recording available from around 2 p.m. CET at:www.bayer.com/live-mc
Additional information for investors, including presentation charts, and access to the live broadcast of the Investor Video Call (from around 2 p.m. CET) and recording (from around 6 p.m. CET) available at:www.bayer.com/live-ic
Print-quality photos can be found online at:www.bayer.com/photo-footage
Find more information atwww.bayer.com.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website atwww.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Bayer AG is a holding company with operating subsidiaries worldwide. References to "Bayer" or "the company" herein may refer to one or more subsidiaries as context requires.
Christian Hartel Head of Corporate Media Relations christian.hartel@bayer.com |
Tino Andresen Corporate Media Relations tino.andresen@bayer.com |
Contact for investor inquiries: Bayer Investor Relations Team ir@bayer.com |
- 2026-0193e.pdf
- 2026-0193e.rtf